Internal Medicine, Endocrinology, Diabetes, & Metabolism · Richmond, VA
NPI
1952336026
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5875 Bremo Road, Suite 501
Richmond, VA, 23226
Phone (804) 282-9899
Groups this clinician bills Medicare through
Medicare paid, 2024
$116K
1,915 services
Medicare patients, 2024
871
Average age 74
Drug cost, 2024
$3.1M
10,186 prescriptions
Company payments, 2025
$851
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert P Castellucci was code 99213 (office e&m - established), 882 times for 572 patients. In total Robert P Castellucci billed 1,915 services in 14 codes, and Medicare paid $116K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-08-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 882 | 572 | $57.37 | $51K |
| 99214 Office E&M - Established | Office | 623 | 346 | $82.89 | $52K |
| 99212 Office E&M - Established | Office | 143 | 121 | $34.19 | $4,890 |
| 36410 Vascular | Office | 93 | 87 | $11.56 | $1,075 |
| 96372 Injection Administration | Office | 86 | 13 | $10.06 | $865 |
| 99204 Office E&M - New | Office | 27 | 27 | $113.35 | $3,060 |
| 99203 Office E&M - New | Office | 23 | 23 | $66.51 | $1,530 |
By year: 2022 $117K for 1,825 services; 2023 $114K for 1,843 services; 2024 $116K for 1,915 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert P Castellucci prescribed most often to Medicare patients was Levothyroxine Sodium, with 898 prescriptions and refills. In total Robert P Castellucci wrote 10,186 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 898 | 2,349 | 237 | $11K |
| Rosuvastatin Calcium Generic | 629 | 1,682 | 182 | $8,378 |
| Metformin Hcl Er Metformin Hcl | 554 | 1,515 | 165 | $7,747 |
| Ozempic Semaglutide | 457 | 748 | 108 | $718K |
| Synthroid Levothyroxine Sodium | 383 | 938 | 102 | $32K |
| Glipizide Er Glipizide | 345 | 930 | 105 | $4,589 |
| Atorvastatin Calcium Generic | 318 | 946 | 89 | $2,756 |
| Jardiance Empagliflozin | 199 | 379 | 45 | $217K |
| Humalog Mix 75-25 Kwikpen Insulin Lispro Protamin/Lispro | 185 | 338 | 38 | $65K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 169 | 344 | 62 | $13K |
| Metformin Hcl Generic | 164 | 425 | 47 | $989 |
| Ezetimibe Generic | 162 | 421 | 48 | $4,104 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 157 | 391 | 50 | $32K |
| Amlodipine Besylate Generic | 136 | 399 | 41 | $825 |
| Janumet Xr Sitagliptin Phos/Metformin Hcl | 129 | 294 | 35 | $152K |
Brand drugs: 4,358 claims; generic drugs: 5,126 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert P Castellucci $851 ($851 in general payments such as food, travel and fees) from 17 companies. The largest payer was Novo Nordisk Inc with $153.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 16 | $153 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 7 | $140 |
| Amgen Inc. AMGN | 12 | $139 |
| CeQur Corporation | 2 | $83.3 |
| Beta Bionics, Inc. BBNX | 4 | $47.08 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41.07 |
| Insulet Corporation PODD | 1 | $35.84 |
| Lilly USA, LLC LLY | 2 | $34.57 |
| Esperion Therapeutics, Inc. ESPR | 2 | $30.5 |
| Xeris Pharmaceuticals, Inc. | 2 | $28.32 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.